Guedes Jéssica de Siqueira, Carneiro Teiliane Rodrigues, Pinheiro Pedro de Sena Murteira, Fraga Carlos Alberto Manssour, Sant Anna Carlos Mauricio R, Barreiro Eliezer J, Lima Lídia Moreira
Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR), Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Universidade Federal do Rio de Janeiro (UFRJ), CCS, Cidade Universitária, Rio de Janeiro-RJ 21941-902, Brazil.
Pós-graduação em Química, Instituto de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ 21941-909, Brazil.
ACS Omega. 2022 Oct 19;7(43):38752-38765. doi: 10.1021/acsomega.2c04368. eCollection 2022 Nov 1.
Sulfonylhydrazones are privileged structures with multifaceted pharmacological activity. Exploring the hypoglycemic properties of these organic compounds, we previously revealed a new series of -sulfonylhydrazones (NSH) as antidiabetic drug candidates. Here, we evaluated the microsomal metabolism, chemical stability, and permeability profile of these NSH prototypes, focusing on the pharmacokinetic differences in -methylated and non--methylated analogs. Our results demonstrated that the -methylated analogs (LASSBio-1772 and LASSBio-1774) were metabolized by CYP, forming three and one metabolites, respectively. These prototypes exhibited chemical stability at pH 2.0 and 7.4 and brain penetration ability. On the other hand, non--methylated analogs (LASSBio-1771 and LASSBio-1773) were hydrolyzed in acid pH and could not cross the artificial blood-brain barrier. The cyano group in LASSBio-1771 was postulated as a possible site of interaction with the heme group, potentially inhibiting CYP enzymes. Moreover, prototypes with the methyl ester group were metabolized by carboxylesterase, and non--methylated analogs did not show oxidative metabolism. The prototypes (except LASSBio-1774) showed excellent gastrointestinal absorption. Altogether, our data support the idea that the methyl effect on NSH strongly alters their pharmacokinetic profile, enhances the recognition by CYP enzymes, promotes brain penetration, and plays a protective effect upon acid hydrolysis.
磺酰腙是具有多方面药理活性的优势结构。在探索这些有机化合物的降血糖特性时,我们之前发现了一系列新的磺酰腙(NSH)作为抗糖尿病药物候选物。在此,我们评估了这些NSH原型的微粒体代谢、化学稳定性和通透性特征,重点关注α-甲基化和非α-甲基化类似物的药代动力学差异。我们的结果表明,α-甲基化类似物(LASSBio-1772和LASSBio-1774)被CYP代谢,分别形成三种和一种代谢物。这些原型在pH 2.0和7.4时表现出化学稳定性以及脑渗透能力。另一方面,非α-甲基化类似物(LASSBio-1771和LASSBio-1773)在酸性pH条件下水解,并且不能穿过人工血脑屏障。LASSBio-1771中的氰基被推测为与血红素基团相互作用的可能位点,可能抑制CYP酶。此外,具有甲酯基团的原型被羧酸酯酶代谢,而非α-甲基化类似物未显示出氧化代谢。这些原型(除LASSBio-1774外)表现出优异的胃肠道吸收。总之,我们的数据支持这样一种观点,即甲基对NSH的影响强烈改变其药代动力学特征,增强CYP酶的识别,促进脑渗透,并对酸水解起到保护作用。